EHRA 2023: Late-Breaking Science Video Collection

Published: 18 April 2023

  • Views:

    Views Icon 1766
  • Likes:

    Heart Icon 7
Average (ratings)
No ratings
Your rating


For short, concise coverage of the key data revealed, our accessible Expert Interviews were conducted with select faculty, focussing on the results, applicability and impact on future research and clinical practice. 

About the episode

EHRA 23 – Dr Bruce Wilkoff (Cleveland Clinic, US) joins us on-site to outline the findings of the AdaptResponse randomized study (NCT02205359). 

In AdaptResponse, investigators studied the hypothesis that cardiac resynchronization therapy (CRT) devices which utilised AdaptivCRT® (aCRT) algorithm (Medtronic) had better prognosis in patients with normal atrioventricular conduction and left bundle branch block when directly compared with patients who had received standard CRT devices. 

1. What was the reasoning behind this study?
2. What was the patient population and study design?
3. What are the main findings?
4. How should these findings be implemented in clinical practice?
5. What are the next steps?

Recorded on-site at EHRA 2023, Barcelona.
Editor: Jordan Rance

Faculty Biographies

Bruce Wilkoff

Bruce Wilkoff


Dr Bruce Wilkoff is the Director of Cardiac Pacing and Tachyarrhythmia Devices and a staff cardiologist at Cleveland Clinic Main Campus, Cleveland, US.

Dr Wilkoff is also a Professor of Medicine at Cleveland Clinic Lerner College of Medicine at Case Western Reserve University. He is board-certified in internal medicine, cardiovascular disease and a Certified Cardiac Device Specialist. 

His clinical interests include abnormal heart rhythms, bradyarrhythmias, sudden cardiac death, lead extraction, implantable cardioverter defibrillator and more.

View full profile


You must be to comment. If you are not registered, you can register here.